Anti-renal interstitial fibrosis Sanhuang prescription and metabonomics research method thereof

Through LC-Q-TOF/MS technology and metabolomics methods, the active ingredients and metabolites of Sanhuang prescription were screened out, which solved the problem that the mechanism of Sanhuang prescription in the treatment of renal interstitial fibrosis in the existing technology was not effectively explored. An assessment of its therapeutic effect and safety was achieved.

CN118903260AActive Publication Date: 2024-11-08JIANGSU PROVINCIAL HOSPITAL OF TCM
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410958173.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08
Estimated Expiration
2044-07-17

AI Technical Summary

Technical Problem

The prior art has failed to effectively detect the active ingredients and metabolomics of Sanhuang Prescription, and cannot in-depth exploration of its therapeutic mechanism and safety for renal interstitial fibrosis.

Method used

Using LC-Q-TOF/MS technology combined with metabolomics, the active ingredients of Sanhuang formula and its metabolites that are significantly different before and after the animal model of interstitial fibrosis of renal interstitial fibrosis were screened. The extraction solution was prepared, standard solution preparation and Mass spectrometry analysis is carried out to identify and characterize metabolites in steps such as animal model preparation.

Benefits of technology

The active ingredients and metabolites of Sanhuang Prescription were successfully screened, revealing its potential mechanism of action in the treatment of renal interstitial fibrosis and evaluating its safety and effectiveness, providing a scientific basis for clinical use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903260A_ABST
    Figure CN118903260A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-renal interstitial fibrosis Sanhuang prescription and a metabonomics research method thereof.The Sanhuang prescription is composed of astragalus membranaceus, abelmoschus manihot and rheum officinale, optimal chromatographic conditions and mass spectrum conditions are screened out through a large number of experiments, and LC-Q-TOF / MS analysis is conducted on active ingredients and metabolites of the Sanhuang prescription; through combination of chemical composition analysis and metabolome analysis, the active components of the Sanhuang prescription and metabolites which are obviously different before and after intervention of rats with renal interstitial fibrosis can be relatively comprehensively, effectively and reliably revealed, and the method has important significance for exploring the potential action mechanism of the Sanhuang prescription for resisting renal interstitial fibrosis and evaluating the safety and effectiveness of the Sanhuang prescription for resisting renal interstitial fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicine detection, and specifically relates to an active ingredient of Sanhuang prescription and a metabolomics research method thereof. Background Art

[0002] Sanhuang Fang is composed of Astragalus, Hibiscus hibiscus flower and Rhubarb. Clinical experimental results show that it has a good anti-renal interstitial fibrosis effect. Currently, there are no reports on the quality detection method of Sanhuang Fang and its metabolomics method.

[0003] Metabolomics analysis uses biological samples as the detection object, with the main purpose of detecting and screening metabolites with important biological significance and significant statistical differences, and on this basis, elucidating the metabolic process and change mechanism of the organism. By screening the results of differential metabolites and metabolic pathway analysis, the relevant functions of the metabolites of the samples are predicted and analyzed.

[0004] The present invention screened out the active ingredients of Sanhuang Fang and screened the metabolites with significant differences in the animal model of renal interstitial fibrosis based on metabolomics and LC-Q-TOF / MS, which is of great significance for exploring the active ingredients of Sanhuang Fang and the potential mechanism of action of Sanhuang Fang in intervening in the animal model of renal interstitial fibrosis, and provides a scientific basis for the medication of patients with clinical renal interstitial fibrosis. Summary of the invention

[0005] Purpose of the invention: The purpose of the present invention is to overcome the shortcomings of the prior art and develop a method for detecting the active ingredients of Sanhuang Fang and a metabolomics research method. The method of the present invention can screen out the active ingredients of Sanhuang Fang and screen out metabolites with significant differences before and after Sanhuang Fang intervenes in an animal model of renal interstitial fibrosis, which is of great significance for exploring the potential mechanism of action of Sanhuang Fang in treating renal interstitial fibrosis and evaluating its safety and effectiveness.

[0006] Technical solution: To achieve the above purpose, the technical solution adopted by the present invention is:

[0007] A traditional Chinese medicine composition for resisting renal interstitial fibrosis comprises astragalus, hibiscus flower and rhubarb.

[0008] As a preferred embodiment, the Chinese medicine composition for resisting renal interstitial fibrosis is characterized in that it is composed of 30-90 parts of astragalus, 30-90 parts of hibiscus flowers, and 10-30 parts of rhubarb.

[0009] A method for detecting active ingredients of a new Sanhuang prescription comprises the following steps:

[0010] (1) Preparation of Xinsanhuangfang Extract:

[0011] Take astragalus, hibiscus flower and rhubarb according to weight ratio, add water to boil and extract, take the decoction, collect the decoction extract after filtering, combine the decoction extract, concentrate, and obtain the new three yellow prescription extract;

[0012] (2) Preparation of mixed standard solution

[0013] Gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, rhein, chrysophanol, and physophanol methyl ether were weighed separately to prepare a single reference solution;

[0014] Then, the single reference substance solutions of the above-mentioned gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, emodin, chrysophanol and physophanol methyl ether are respectively taken, mixed evenly, and diluted to obtain a mixed standard solution;

[0015] (3) Analysis of components of the extract of Xinsanhuangfang

[0016] Take the extract of Xin Sanhuang Fang in step (1), centrifuge it, and inject the centrifuged liquid into LC-Q-TOF / MS for analysis.

[0017] A metabolomics research method for a new Sanhuang recipe comprises the following steps:

[0018] (1) Preparation of Xinsanhuangfang Extract:

[0019] Take astragalus, hibiscus flower and rhubarb according to weight ratio, add water to boil and extract, take the decoction, collect the decoction extract after filtering, combine the decoction extract, concentrate, and obtain the new three yellow prescription extract;

[0020] (2) Preparation of mixed standard solution

[0021] Gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, rhein, chrysophanol, and physophanol methyl ether were weighed separately to prepare a single reference solution;

[0022] Then, the single reference substance solutions of the above-mentioned gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, emodin, chrysophanol and physophanol methyl ether are respectively taken, mixed evenly, and diluted to obtain a mixed standard solution;

[0023] (3) Animal model and serum preparation:

[0024] Male SD rats were randomly divided into a normal control group and a renal interstitial fibrosis animal model group 14 days after modeling; the rats in the normal group and the model group were gavaged with the Xin Sanhuang Fang extract prepared in step (1), and blood was collected from the rats' eye sockets; then the plasma was processed to obtain a serum sample solution;

[0025] (4) Analysis of metabolic components of Xin Sanhuang Fang

[0026] The mixed standard solution of step (2) and the serum sample of step (3) are injected into a liquid chromatography-mass spectrometer (LC-Q-TOF / MS) for analysis;

[0027] (5) The mass spectrometry data of the Sanhuang Fang extract and plasma samples collected by LC-Q-TOF / MS were processed, and the metabolites of Sanhuang Fang were identified and characterized after comparison and analysis with the reference substances and the database.

[0028] As a preferred embodiment, in the method described above, step (1) is: taking astragalus, hibiscus flower and rhubarb in a weight ratio of 3:3:1, adding 8 to 16 times the volume of water and decocting and extracting twice, each extraction time is 30 to 120 minutes, filtering and collecting the decoction extract, combining the decoction extracts, and concentrating to obtain the Xin Sanhuang Fang extract.

[0029] As a preferred embodiment, in the method described above, the preparation method of the mixed standard solution in step (2) is:

[0030] Weigh astragaloside IV, dilute with 50% ethanol containing 30% DMSO to obtain a 2 mg / mL astragaloside IV stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0031] Weigh the calycosin isoflavone glucoside, dilute it with 50% ethanol to obtain a 1 mg / mL calycosin isoflavone glucoside stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0032] Weigh ferulic acid, dilute with methanol to obtain a ferulic acid stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0033] Weigh kaempferol, dilute with methanol to obtain a 1 mg / mL kaempferol stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0034] Weigh quercetin, dilute with methanol to obtain a quercetin stock solution with a concentration of 2 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0035] Weigh Hypericum wilfordii, dilute with 50% methanol to obtain a 1 mg / mL hyperoside stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0036] Weigh aloe-emodin, dilute with ethanol and DMSO in a volume ratio of 1:1 to obtain a 2 mg / mL aloe-emodin stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0037] Weigh rhein, dilute with ethanol:DMSO in a volume ratio of 1:1 to obtain a 1 mg / mL rhein stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0038] Take rheumatoid artemisia, dilute it with ethanol:DMSO in a volume ratio of 1:1 to obtain a rheumatoid artemisia stock solution with a concentration of 1 mg / mL, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0039] Weigh chrysophanol, dilute it with ethanol:DMSO in a volume ratio of 5:13 to obtain a 2.00 mg / mL chrysophanol stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0040] Weigh physcion methyl ether, dilute it with a mixture of ethanol and DMSO in a volume ratio of 5:13 to obtain a physcion methyl ether stock solution with a concentration of 0.572 mg / mL, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0041] Weigh gallic acid and dilute it with 50% methanol to obtain a 1 mg / mL gallic acid stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0042] Weigh epicatechin, dilute with methanol to obtain an epicatechin stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0043] Weigh scopoletin, dilute with 50% ethanol to obtain a scopoletin stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0044] Preparation of mixed standard solution

[0045] The above-mentioned single standard solutions of astragaloside IV, calycosin glucoside, ferulic acid, kaempferol, quercetin, hyperoside, aloe-emodin, rhein, rhein, chrysophanol, physophanol methyl ether, gallic acid, epicatechin and scopoletin, all of which have a concentration of 100 μg / mL, were mixed evenly, and diluted with 50% methanol to obtain a mixed standard solution in which the concentration of each compound was 2.00 μg / mL.

[0046] As a preferred embodiment, in the above-mentioned metabolomics research method of Sanhuang Fang, the animal model and serum preparation method in step (3) are:

[0047] Male SD rats were randomly divided into a normal control group and a renal interstitial fibrosis animal model group; 14 days after modeling, the rats in the normal and model groups were gavaged with the Xin Sanhuang Fang extract prepared in step (1) at a dose of 7.25 g / kg, and blood was collected from the rats' orbits at 0 h, 0.5 h, 1 h, 2 h, and 4 h after administration;

[0048] Take 200 μL of plasma, add 800 μL of methanol, vortex for 1 min, centrifuge at 12000 rpm and 4°C for 10 min, take 900 μL of supernatant, blow dry at 40°C, add 100 μL of 50% methanol to the residue, vortex for 1 min, centrifuge at 12000 rpm and 4°C for 10 min, take 80 μL of supernatant, centrifuge at 12000 rpm and 4°C for 10 min to obtain a serum sample solution.

[0049] As a preferred embodiment, in the method described above, the liquid chromatography conditions for LC-Q-TOF / MS analysis in step 4 are:

[0050] Chromatographic column: Agilent SB C18, size 4.6mm×100mm, 1.8μm; mobile phase: phase A: 0.1% formic acid aqueous solution, phase B: methanol and acetonitrile in a volume ratio of 1:1, column temperature: 40°C, gradient elution; gradient elution program is as follows:

[0051] Time min <![CDATA[Flow rate mL·min -1 > A% B% 0 0.40 85 15 2.5 0.40 80 20 7.0 0.40 75 25 12.0 0.40 50 50 19.0 0.40 10 90 21.0 0.40 10 90 28.0 0.55 40 60 31.0 0.55 85 15 35.0 0.40 85 15 .

[0052] The mass spectrometry conditions for the LC-Q-TOF / MS analysis are:

[0053] Q-TOF / MS analysis adopted ESI source positive and negative ion scanning mode, negative ion source voltage was -4500V, ion source temperature was 550℃, nebulizer gas was N2, primary mass spectrometry scanning range: m / z100~1000, DP: 80V; GS1: 50, GS2: 60, CUR: 20, CE: 10eV; IDA mode was adopted to collect secondary mass spectrometry data, collection range: 90~1000, DP: 100V, CE: 25eV; CES: 15; positive ion source voltage was 5500V, ion source temperature was 550℃, nebulizer gas was N2, primary mass spectrometry scanning range: m / z 100~1000, DP: 100V; GS1: 50, GS2: 60, CUR: 20, CE: 10eV; IDA mode was used to collect secondary mass spectrometry data, with a collection range of 90~1000, DP: 100V, CE: 30eV;

[0054] CES: 15; IDA was set to perform secondary mass spectrometry scanning on the 10 highest peaks with response signal intensity > 100 cps, and dynamic background subtraction was turned on.

[0055] The beneficial effect is that the present invention screens out the Sanhuang Recipe (Astragalus, Hibiscus Flower, Rhubarb) with anti-renal interstitial fibrosis through a large number of experiments. The optimal chromatographic conditions and mass spectrometry conditions are screened out through a large number of experiments to perform LC-Q-TOF / MS analysis on the active ingredients and metabolites of the Sanhuang Recipe, and the combination of chemical group analysis and metabolomic analysis can relatively comprehensively, effectively and reliably reveal the active ingredients of the Sanhuang Recipe and the metabolites that significantly differ before and after administration in an animal model of renal interstitial fibrosis, which is of great significance for exploring the potential mechanism of action of the Sanhuang Recipe in treating animals with renal interstitial fibrosis and evaluating its safety and effectiveness. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 This is the BPC diagram of the LC-Q-TOF / MS of the new Sanhuang Fang standard.

[0057] Figure 2 This is the TIC diagram of the new Sanhuang recipe LC-Q-TOF / MS (the upper figure is positive ion, and the lower figure is negative ion).

[0058] Figure 3 This is the XIC diagram of the new Sanhuang Fang LC-Q-TOF / MS in positive ion mode (the upper figure is the normal figure, and the lower figure is the local enlarged figure).

[0059] Figure 4 This is the XIC diagram of Xin Sanhuang Fang LC-Q-TOF / MS in negative ion mode (the upper figure is the normal figure, and the lower figure is the local enlarged figure).

[0060] Figure 5 LC-Q-TOF / MS TIC graph of plasma of normal rats after oral administration of Xinsanhuang Recipe (positive ion) (dark blue, purple, red, green and light blue are the plasma of blank and 0.5h, 1h, 2h and 4h after administration, respectively).

[0061] Figure 6 TIC diagram (positive ion) of plasma LC-Q-TOF / MS of model rats after gavage of Xinsanhuang Recipe (dark blue, purple, red, green and light blue represent the blank and plasma 0.5h, 1h, 2h and 4h after administration, respectively).

[0062] Figure 7 TIC graph (negative ion) of plasma LC-Q-TOF / MS of normal rats after oral administration of Xinsanhuang Recipe (dark blue, purple, red, green and light blue represent the blank and plasma 0.5h, 1h, 2h and 4h after administration, respectively).

[0063] Figure 8TIC diagram (negative ion) of plasma LC-Q-TOF / MS of model rats after gavage of Xinsanhuang Recipe (dark blue, purple, red, green and light blue represent the blank and plasma 0.5h, 1h, 2h and 4h after administration, respectively).

[0064] Fig. 9 Statistical chart of plasma migration components (prototype + metabolite prototype) in rats after oral administration of Xinsanhuang Decoction.

[0065] Fig.10 Changes of liver and kidney function in UUO rats after intervention with Xinsanhuang Fang extract.

[0066] Fig.11 Effect of Xinsanhuangfang extract on renal fibrosis in UUO rats 14 days after modeling.

[0067] Fig.12 Effects of Xinsanhuangfang freeze-dried powder on HK-2 cells.

[0068] Fig.13 The new Sanhuang recipe reduces ROS generation and has anti-oxidation effects. DETAILED DESCRIPTION

[0069] The embodiments of the present invention are described in detail below with reference to the examples. If no specific conditions are specified in the examples, the reaction is carried out according to conventional conditions or conditions recommended by the manufacturer. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.

[0070] The reagents and samples of the following examples: astragaloside IV, kaempferol, gallic acid, hyperoside, scopoletin, calycosin glucoside, ferulic acid, quercetin, epicatechin, rhein, physophanol methyl ether, rhein, and chrysophanol were purchased from Shanghai Yuanye Biotechnology Co., Ltd. Methanol and acetonitrile (chromatographic grade, Merck); formic acid (chromatographic grade, Shanghai Chemical Reagent Co., Ltd.); and ultrapure water was used in the experiments.

[0071] Experimental instruments: AB SCIEX Triple TOF 5600 mass spectrometer; Sartorius CPA225D electronic balance (Sartorius, Germany); Biofuge PrimoR refrigerated high-speed centrifuge (Heraeus, Germany); MilliporeDrict-Q ultrapure water machine (Millipore, France); KQ 3200E ultrasonic cleaning machine (Kunshan Ultrasonic Instrument Co., Ltd.); Centri Vap centrifugal concentrator (Labconco); WH-2 micro vortex mixer (Shanghai Huxi Analytical Instrument Factory).

[0072] Example 1

[0073] A metabolomics research method for a new Sanhuang recipe comprises the following steps:

[0074] (1) Preparation of Xinsanhuangfang Extract:

[0075] Take 30g of Astragalus, 30g of Hibiscus hibiscus flower and 10g of Rhubarb, add 8 times volume ratio of water and decoct for 2 times, each time for 40 minutes, collect the decoction extract after filtering, combine the decoction extract, and concentrate it by rotary evaporator at 50℃ and 200 rpm to obtain the Xin Sanhuang Fang extract with a concentration of 5g / ml;

[0076] (2) Preparation of mixed standard solution

[0077] Weigh astragaloside IV, dilute with 50% ethanol containing 30% DMSO to obtain a 2 mg / mL astragaloside IV stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0078] Weigh the calycosin isoflavone glucoside, dilute it with 50% ethanol to obtain a 1 mg / mL calycosin isoflavone glucoside stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0079] Weigh ferulic acid, dilute with methanol to obtain a ferulic acid stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0080] Weigh kaempferol, dilute with methanol to obtain a 1 mg / mL kaempferol stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0081] Weigh quercetin, dilute with methanol to obtain a quercetin stock solution with a concentration of 2 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0082] Weigh Hypericum wilfordii, dilute with 50% methanol to obtain a 1 mg / mL hyperoside stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0083] Weigh aloe-emodin, dilute with ethanol and DMSO in a volume ratio of 1:1 to obtain a 2 mg / mL aloe-emodin stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0084] Weigh rhein, dilute with ethanol:DMSO in a volume ratio of 1:1 to obtain a 1 mg / mL rhein stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0085] Take rheumatoid artemisia, dilute it with ethanol:DMSO in a volume ratio of 1:1 to obtain a rheumatoid artemisia stock solution with a concentration of 1 mg / mL, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0086] Weigh chrysophanol, dilute it with ethanol:DMSO in a volume ratio of 5:13 to obtain a 2.00 mg / mL chrysophanol stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0087] Weigh physcion methyl ether, dilute it with a mixture of ethanol and DMSO in a volume ratio of 5:13 to obtain a physcion methyl ether stock solution with a concentration of 0.572 mg / mL, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0088] Weigh gallic acid and dilute it with 50% methanol to obtain a 1 mg / mL gallic acid stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use;

[0089] Weigh epicatechin, dilute with methanol to obtain an epicatechin stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0090] Weigh scopoletin, dilute with 50% ethanol to obtain a scopoletin stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use;

[0091] Preparation of mixed standard solution

[0092] Take the above-mentioned single standard solutions of astragaloside IV, calycosin glucoside, ferulic acid, kaempferol, quercetin, hyperoside, aloe-emodin, rhein, rhein, chrysophanol, physophanol methyl ether, gallic acid, epicatechin and scopoletin, all with a concentration of 100 μg / mL, mix them evenly, and dilute them with 50% methanol to obtain a mixed standard solution with a concentration of each compound of 2.00 μg / mL.

[0093] (3) Animal model and serum preparation:

[0094] Male SD rats were randomly divided into a normal control group and a renal interstitial fibrosis animal (UUO) model group (UUO modeling method: rats were fasted for 12 hours, weighed, anesthetized with isoflurane at a concentration of 2-3% and maintained with 1.5-2%, and the limbs were fixed. Routine disinfection was performed, a 2 cm incision was made in the left lower abdomen, the left ureter was freed, the ureter was ligated twice along the lower pole of the left kidney, and the ureter was cut from the middle); 14 days after modeling, the rats in the normal and model groups were gavaged with the Xin Sanhuang Fang extract prepared in step (1) at 7.25 g / kg, and blood was collected from the rats' orbits at 0 h, 0.5 h, 1 h, 2 h and 4 h after administration;

[0095] Take 200 μL of plasma, add 800 μL of methanol, vortex for 1 min, centrifuge at 12000 rpm and 4°C for 10 min, take 900 μL of supernatant, blow dry at 40°C, add 100 μL of 50% methanol to the residue, vortex for 1 min, centrifuge at 12000 rpm and 4°C for 10 min, take 80 μL of supernatant, centrifuge at 12000 rpm and 4°C for 10 min to obtain a serum sample solution.

[0096] (4) Analysis of metabolic components of Xin Sanhuang Fang

[0097] The decoction in step (1) was brought to room temperature and vortexed to mix. 100 μL of the decoction was added with 900 μL of 50% methanol, vortexed to mix, ultrasonicated for 20 min, centrifuged at 12000 rpm and 4°C for 10 min, and 5 μL of the supernatant decoction sample was injected into the LC-Q-TOF / MS for analysis.

[0098] In addition, 5 μL of the mixed standard solution in step (2) and the serum sample in step (3) were injected into the LC-Q-TOF / MS for analysis;

[0099] (5) The mass spectrometry data of the Sanhuang Fang extract and plasma samples collected by LC-Q-TOF / MS were processed, and the metabolites of Sanhuang Fang were identified and characterized after comparison and analysis with the reference substances and the database.

[0100] The liquid chromatography conditions for the LC-Q-TOF / MS analysis are:

[0101] Chromatographic column: Agilent SB C18, size 4.6mm×100mm, 1.8μm; mobile phase: phase A: 0.1% formic acid aqueous solution, phase B: methanol and acetonitrile in a volume ratio of 1:1, column temperature: 40°C, gradient elution; the gradient elution program is as shown in Table 1:

[0102] Table 1

[0103] Time min <![CDATA[Flow rate mL·min -1 > A% B% 0 0.40 85 15 2.5 0.40 80 20 7.0 0.40 75 25 12.0 0.40 50 50 19.0 0.40 10 90 21.0 0.40 10 90 28.0 0.55 40 60 31.0 0.55 85 15 35.0 0.40 85 15 .

[0104] The mass spectrometry conditions for the LC-Q-TOF / MS analysis are:

[0105] R-TOF / MS analysis adopted ESI source positive and negative ion scanning mode, negative ion source voltage was -4500V, ion source temperature was 550℃, nebulizer gas was N2, primary mass spectrometry scanning range: m / z100~1000, DP: 80V; GS1: 50, GS2: 60, CUR: 20, CE: 10eV; IDA mode was adopted to collect secondary mass spectrometry data, collection range: 90~1000, DP: 100V, CE: 25eV; CES: 15; positive ion source voltage was 5500V, ion source temperature was 550℃, nebulizer gas was N2, primary mass spectrometry scanning range: m / z 100~1000, DP: 100V; GS1: 50, GS2: 60, CUR: 20, CE: 10eV; IDA mode was used to collect secondary mass spectrometry data, with a collection range of 90~1000, DP: 100V, CE: 30eV;

[0106] CES: 15; IDA was set to perform secondary mass spectrometry scanning on the 10 highest peaks with response signal intensity > 100 cps, and dynamic background subtraction was turned on.

[0107] (6) Analysis results

[0108] (6.1) Chromatographic behavior of each standard

[0109] Under the above GC-MS conditions, the retention times of gallic acid, epicatechin, calycosin glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, rhein, chrysophanol, and physophanol methyl ether were approximately 4.0, 9.0, 12.2, 12.5, 12.7, 13.0, 15.8, 17.3, 19.5, 20.2, 21.0, 21.8, 22.6, and 23.4 min, respectively (see Table 1 ). Figure 1 and Table 2.

[0110] Table 2 LC-Q-TOF / MS data information of each standard substance of Xinsanhuang Fang

[0111]

[0112] 2.2 Construction of the new Sanhuang Fang compound library

[0113] The literature and TCMSP database were consulted to build compound libraries of Amur sunflower, Astragalus membranaceus and Rheum officinale, respectively. Among them, there were 59 Amur sunflower compounds, 153 Astragalus membranaceus compounds and 307 Rheum officinale compounds. After deduplication, a total of 468 compounds were found, and the structural formula of each compound was drawn for the identification and characterization of compounds in Sanhuang Recipe and plasma samples.

[0114] 2.3 Identification and characterization of the chemical substances in the new Sanhuang recipe

[0115] After comparison with standard products, literature and compound fragment information, 67 compounds were identified from the Xin Sanhuang formula.

[0116] Compounds, including 7 phenolic acid compounds, 3 nucleotide compounds, 32 flavonoids (glycosides), 5 chromones (glycosides), 10 anthraquinones, 5 amino acids, and 5 others; 14 from sunflower seeds, 23 from astragalus, 25 from rhubarb, astragalus and sunflower seeds have 4 common components, astragalus and rhubarb have 1 common component. The LC-Q-TOF / MS chromatogram of Sanhuang Fang (including total ion current TIC and extracted ion current XIC of all identified compounds in positive and negative ion modes) is shown in Figures 2 to 4 The data information of LC-Q-TOF / MS and the identification results of each compound are shown in Tables 3 to 8 (partial).

[0117] Table 3 LC-Q-TOF / MS data information of the new Sanhuang Fang samples and identification results of each compound

[0118]

[0119] Table 4

[0120]

[0121] Table 5

[0122]

[0123] Table 6

[0124]

[0125] Table 7

[0126]

[0127] Table 8

[0128]

[0129] Table 9

[0130]

[0131] Note: * is compared with the standard

[0132] By comparing the component library of the decoction of Xin Sanhuang Fang and references, a total of 27 possible metabolites, including gallic acid, 2-(2'-hydroxypropyl)-5-methyl-7-hydroxychromone-7-O-β-D-pyranoglucopyranoside, formononetin, 6-methylrhein, aloe-emodin, rhein and rhein, which are the characteristic prototype components of 7 prescriptions (excluding the components common in the decoction and medicinal materials such as nucleotides, amino acids and vitamins), and quercetin glucuronide conjugate and gossypirin / myricetin glucuronide conjugate, were identified in the plasma of rats that were gavaged with Xin Sanhuang Fang. The results are shown in Tables 10 to 12.

[0133] Table 10

[0134]

[0135] Table 11

[0136]

[0137]

[0138] Table 12

[0139]

[0140] Note: ND means not detected; Glu means glucuronic acid conjugate; SO3 means sulfate conjugate

[0141] LC-Q-TOF / MS chromatograms of plasma samples of rats after oral administration of Xinsanhuang Fang (TIC graphs in positive and negative ion modes) are shown in Figures 5 to 8 Plasma transition components in rats after oral administration of Xin Sanhuang Fang Fig. 9 .

[0142] Example 2: Pharmacological Effect Experiment of Sanhuang Prescription

[0143] 1. Experimental animals and cells

[0144] Male SD rats aged 6-8 weeks (Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd.) weighing 250±50g were selected and kept in the Basic Pharmacology Laboratory of the Affiliated Hospital of Nanjing University of Chinese Medicine (Nanjing, Jiangsu). License number: SYXK (Su) 2022-0070. All animals were given free access to water and food, and were randomly divided into groups for experiments after 1 week of adaptive feeding. The feeding conditions were humidity 50±5%, room temperature 20℃, and lighting alternating for 12h. Human renal proximal tubular cells (HK-2) cell line was provided by the Cell Bank of the Chinese Academy of Sciences.

[0145] 2. Experimental methods

[0146] 2.1 Animal experiments

[0147] 2.1.1 After 1 week of adaptive feeding, 35 SD rats were randomly divided into 5 groups, 7 rats in each group: normal control group (normal saline gavage); renal interstitial fibrosis (UUO) model group; UUO + low-dose Xinsanhuang Fang group (Xinsanhuang Fang water decoction 5.42g / kg / d gavage); UUO + high-dose Xinsanhuang Fang group (Xinsanhuang Fang water decoction 10.85g / kg / d gavage); UUO + metformin group (metformin 65mg / kg / d), Xinsanhuang Fang gavage was given for 4 weeks after the modeling began. No antibiotics were used in all groups. Gavage began 1 week before modeling. The gavage volume of rats in each group was 10ml / kg, once a day, and the time was fixed.

[0148] Dosage calculation: New Sanhuang Recipe (30g of Astragalus, 30g of Hibiscus Flower, 10g of Rhubarb) The rhubarb described in the present invention is cooked rhubarb unless otherwise specified.

[0149] The dosage of Xin Sanhuang Fang in the low-dose group = clinical low dose (35g) / 60kg / day × rat equivalent area dose coefficient (6.3); the dosage of Xin Sanhuang Fang in the high-dose group = clinical low dose (770g) / 60kg / day × rat equivalent area dose coefficient (6.3)

[0150] New Sanhuang Decoction Water Decoction: Take 30g of Astragalus, 30g of Hibiscus Flower, and 10g of Rhubarb, add 8 times the amount of water, decoct and extract for 40 minutes, filter and collect the filtrate, add 8 times the amount of water again, decoct and extract for 40 minutes, filter and collect the filtrate. Mix the two filtrates and filter them with medical gauze, then concentrate them in a rotary evaporator at 50℃ and 200 rpm. The concentrate is stored at -80℃. After 24 hours, place it in a freeze dryer, set the vacuum mode, 0.25mBar, and the temperature to -50℃, and finally freeze-dry it into powder. It is usually sealed and stored in a -20℃ refrigerator. Weigh an appropriate amount of freeze-dried powder, dissolve it in PBS to form a mother solution of the prescription water extract (1g / mL), and then filter it with a 0.22μm filter. The filtered mother solution is divided and stored at -20℃.

[0151] 2.1.2 Specimen collection

[0152] Fast for 12 hours in the fourth week after modeling. Rats were weighed and anesthetized with isoflurane gas anesthesia. The abdominal cavity was cut open and blood was collected from the abdominal aorta to obtain blood samples. After separating and exposing the kidney, the left kidney tissue was cut, the capsule was removed, and the kidney size was measured after washing with PBS. The kidney was weighed and recorded. The kidney was cut into two parts, one part was fixed in 4% paraformaldehyde for paraffin section preparation, and then immunohistochemical staining and HE staining were performed. One part was placed in a cryovial, quickly frozen in liquid nitrogen overnight, and then transferred to a -80℃ refrigerator for storage.

[0153] 2.1.3 Detection indicators

[0154] ① Use a biochemical analyzer to detect liver and kidney function indicators (Cr, BUN, ALT and AST, etc.) in blood samples.

[0155] ②Western-blot was used to detect α-SMA, Fibronectin, E-cadherin, SOD 2 and VDAC2 related proteins.

[0156] ③Fresh kidney tissue was stained with DHE to observe the changes in ROS expression in kidney tissue; after the kidney tissue was embedded in wax blocks, it was stained with HE and MASSON, and α-SMA, Fibronectin, and E-cadherin tissue fluorescence staining was performed.

[0157] 2.2 In vivo experiments

[0158] 2.2.1 Cell grouping and model preparation:

[0159] HK-2 cells were cultured in DMEM / F12 medium + 10% Gibc fetal bovine serum + 1% penicillin-streptomycin in an incubator at 37°C and 5% CO2. P4-P10 HK-2 cells in logarithmic phase with good growth were selected and plated at 1×10 cells per well. 5 Cells were inoculated into 6-well plates and cultured at 37°C and 5% CO2 saturated humidity. When the cell fusion reached 50% to 60%, they were grouped according to the experimental purpose:

[0160] The effects of Xin San Huang Fang freeze-dried powder on HK-2 cells after TGF-β stimulation were investigated: ① Normal group: cultured in DMEM / F12 medium; ② TGF-β group: TGF-β was added to the culture medium at a final concentration of 10 ng / ml; ③ TGF-β+Xin San Huang Fang freeze-dried powder: TGF-β+Xin San Huang Fang freeze-dried powder (0.1, 0.5,

[0161] ④TGF-β+Metformin: TGF-β+Metformin (1mmol / L) medium was used for culture. Note: TGF-β and Xin San Huang Fang freeze-dried powder were used to treat cells for 24h.

[0162] 2.2.2 Detection indicators

[0163] ① After 24 hours of TGF-β and drug intervention, the cells were photographed and preserved under an optical microscope.

[0164] ②Extract cell proteins from each group, and use Western-blot to detect α-SMA, Fibronectin, E-cadherin, AMPK and p-AMPK, SOD 2 and VDAC2 related proteins; find the optimal concentration of drug intervention.

[0165] ③ The cells were cultured in 35 mm dishes and divided into normal group, TGF-β, TGF+Xin Sanhuang Fang freeze-dried powder, and TGF-β+metformin intervention groups. After 24 h, mitochondrial ROS staining was performed and photographs were taken under a confocal microscope. Fibrosis antibodies (Fibronectin, E-cadherin, and α-SMA) were used for staining and photographs were taken under a confocal microscope.

[0166] 2.3 Data Statistics and Analysis

[0167] SPSS 26.0 statistical software was used, and the measurement data were described by mean ± standard deviation (±s); the comparison between two groups was performed by t test, the comparison between multiple groups was performed by one-way analysis of variance, and the comparison between two groups was performed by Tukey or Dunnett test. With α = 0.05 as the level, when P < 0.05, the difference was statistically significant.

[0168] 3. Experimental results

[0169] 3.1 Changes of liver and kidney function in UUO rats after intervention with Xinsanhuang Fang extract

[0170] like Fig.10 , urea nitrogen and creatinine in UUO rats were significantly higher than those in the normal group. After oral administration of the Xin Sanhuang Recipe decoction, both low and high doses could alleviate the deterioration of renal function in rats. At the same time, no obvious abnormalities were found in the liver function (alanine aminotransferase and aspartate aminotransferase) of rats given the Xin Sanhuang Recipe.

[0171] 3.2 Effect of Xinsanhuangfang extract on renal fibrosis in UUO rats 14 days after modeling

[0172] like Fig.11 As shown in the figure. 14 days after UUO modeling, the rat kidneys were significantly enlarged and the cortex was thinned. HE and Masson staining results showed that the renal tubules were significantly dilated, the tubular epithelial villi disappeared, the renal interstitium was widened, and the degree of interstitial fibrosis was aggravated; after intervention with Xinsanhuang Fang, the above morphological changes were alleviated, and with the increase of Xinsanhuang drug dose, renal interstitial fibrosis was further alleviated. Renal tissue immunofluorescence and Western-blot showed that compared with the normal group, the expression of Fbironectin and α-SMA proteins in renal tissues was significantly increased. After treatment with Xinsanhuang Fang, the expression of the above two proteins gradually decreased with the increase of drug dose; the expression of E-cadherin, a marker protein of renal tubular epithelium, was significantly reduced in the UUO group, and the expression was gradually enhanced after treatment with Xinsanhuang Fang.

[0173] 3.3 Effects of Xinsanhuang Fang freeze-dried powder on HK-2 cells

[0174] like Fig.12 , under light microscopy, normal cells showed a cobblestone-like morphology. After TGF-β stimulation, the cells became spindle-shaped. After treatment with Xinsanhuang Fang freeze-dried powder, as the drug concentration increased, the cells gradually changed from spindle-shaped to cobblestone-like. When the drug concentration was 5 mg / L, the cells changed into a cobblestone-like morphology. At the same time, Western-blot showed that the protein expression of fibrosis indicators (Fbironectin and α-SMA) increased significantly after TGF-β stimulation. After intervention with Xinsanhuang Fang freeze-dried powder, as the drug concentration increased, the expression of the above two proteins gradually decreased. When the concentration of Xinsanhuang Fang freeze-dried powder was 5 mg / L, the expression of Fbironectin and α-SMA reached the lowest value. The expression of E-cadherin, a marker protein of renal tubular epithelial cells, showed an opposite trend to the above two indicators. After TGF-β stimulation, 5 mg / L Xin San Huang Fang freeze-dried powder was given to intervene. Immunofluorescence showed that the expression of Fbironectin and α-SMA in the cytoplasm increased significantly. After intervention with Xin San Huang Fang freeze-dried powder, the distribution of the above two proteins in the cytoplasm was significantly weakened. At the same time, the expression of E-cadherin showed an opposite trend.

[0175] 3.4 Xin Sanhuang Fang reduces ROS generation and has antioxidant effects

[0176] like Fig.13 , 14 days after UUO modeling, the generation of ROS in the kidney of rats increased significantly, while in rats given Xin San Huang Fang by gavage, the generation of ROS in the renal cortex decreased significantly, and the high dose was significantly lower than the low dose. Western-blot showed that the expression of renal superoxide dismutase type 2 (SOD 2) and mitochondrial porin 1 (VDAC 1) in UUO rats was significantly reduced, indicating that the antioxidant capacity was impaired. After intervention with Xin San Huang Fang, the expression of the above two proteins increased significantly, and the high dose was better than the low dose; in the cell experiment, after TGF-β stimulation, Western-blot showed that the expression of cell SOD 2 and VDAC 1 decreased significantly, while after intervention with Xin San Huang Fang freeze-dried powder, the expression of the above two proteins increased significantly with the increase of drug concentration, and the protein expression reached a peak at a concentration of 5 mg / L. In the mitochondrial membrane potential detection, normal cells expressed high membrane potential and showed red fluorescence. After TGF-β stimulation, the mitochondria of renal tubular epithelial cells were damaged, the mitochondrial membrane potential decreased, and green light appeared; after intervention with Xin Sanhuang Fang, the fluorescence gradually increased in red, indicating that the damaged mitochondria were significantly reduced. After DHE and mitochondrial ROS staining, it was shown that after TGF-β stimulated renal tubular epithelial cells, the generation of cellular ROS was significantly enhanced, and after intervention with Xin Sanhuang Fang, the generation of cellular ROS was significantly reduced, indicating that Xin Sanhuang Fang has antioxidant capacity.

Claims

1. A Chinese medicine composition for resisting renal interstitial fibrosis, characterized in that: It includes astragalus, hibiscus flower, and rhubarb.

2. A Chinese medicine composition for resisting renal interstitial fibrosis according to claim 1, characterized in that: The invention is composed of 30-90 parts of astragalus, 30-90 parts of hibiscus flower and 10-30 parts of rhubarb.

3. A method for detecting active ingredients of Xin Sanhuang Fang, characterized in that: It includes the following steps: (1) Preparation of Xinsanhuangfang Extract: Take astragalus, hibiscus flower and rhubarb according to weight ratio, add water to boil and extract, take the decoction, collect the decoction extract after filtering, combine the decoction extract, concentrate, and obtain the new three yellow prescription extract; (2) Preparation of mixed standard solution Gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, rhein, chrysophanol, and physophanol methyl ether were weighed separately to prepare a single reference solution; Then, the single reference substance solutions of the above-mentioned gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, emodin, chrysophanol and physophanol methyl ether are respectively taken, mixed evenly, and diluted to obtain a mixed standard solution; (3) Analysis of components of the extract of Xinsanhuangfang Take the extract of Xin Sanhuang Fang from step (1), centrifuge it, take the centrifuge solution, and take the mixed standard solution from step (2), and inject them into the liquid chromatography-mass spectrometer LC-Q-TOF / MS for analysis.

4. A metabolomics research method for a new Sanhuang recipe, characterized in that: It includes the following steps: (1) Preparation of Xinsanhuangfang Extract: Take astragalus, hibiscus flower and rhubarb according to weight ratio, add water to boil and extract, take the decoction, collect the decoction extract after filtering, combine the decoction extract, concentrate, and obtain the new three yellow prescription extract; (2) Preparation of mixed standard solution Gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, rhein, chrysophanol, and physophanol methyl ether were weighed separately to prepare a single reference solution; Then, the single reference substance solutions of the above-mentioned gallic acid, epicatechin, calycosin, glucose, hyperoside, scopoletin, ferulic acid, quercetin, kaempferol, aloe-emodin, rhein, astragaloside I, emodin, chrysophanol and physophanol methyl ether are respectively taken, mixed evenly, and diluted to obtain a mixed standard solution; (3) Animal model and serum preparation: Male SD rats were randomly divided into a normal control group and a renal interstitial fibrosis animal model group 14 days after modeling; the rats in the normal control group and the model group were gavaged with the Xin Sanhuang Fang extract prepared in step (1), and blood was collected from the rats' eye sockets; then the plasma was processed to obtain a serum sample solution; (4) Analysis of metabolic components of Xin Sanhuang Fang The mixed standard solution of step (2) and the serum sample of step (3) are injected into a liquid chromatography-mass spectrometer (LC-Q-TOF / MS) for analysis; (5) The mass spectrometry data of the Sanhuang Fang extract and plasma samples collected by LC-Q-TOF / MS were processed and compared with the reference substances and the database to determine the composition information of the metabolites of Sanhuang Fang.

5. The method according to claim 3 or 4, characterized in that: Step (1): taking astragalus, hibiscus flower and rhubarb in a weight ratio of 3:3:1, adding 8 to 16 times the volume ratio of water, boiling and extracting twice, each extraction time is 30 to 120 minutes, filtering and collecting the boiling extract, combining the boiling extracts, and concentrating to obtain the Xin Sanhuang Fang extract.

6. The method according to claim 3 or 4, characterized in that: Step (2) Preparation of mixed standard solution: Weigh astragaloside IV, dilute with 50% ethanol containing 30% DMSO to obtain a 2 mg / mL astragaloside IV stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Weigh the calycosin isoflavone glucoside, dilute it with 50% ethanol to obtain a 1 mg / mL calycosin isoflavone glucoside stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use; Weigh ferulic acid, dilute with methanol to obtain a ferulic acid stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Weigh kaempferol, dilute with methanol to obtain a 1 mg / mL kaempferol stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Weigh quercetin, dilute with methanol to obtain a quercetin stock solution with a concentration of 2 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Weigh Hypericum wilfordii, dilute with 50% methanol to obtain a 1 mg / mL hyperoside stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Weigh aloe-emodin, dilute with ethanol and DMSO in a volume ratio of 1:1 to obtain a 2 mg / mL aloe-emodin stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Weigh rhein, dilute with ethanol:DMSO in a volume ratio of 1:1 to obtain a 1 mg / mL rhein stock solution, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Take rheumatoid artemisia, dilute it with ethanol:DMSO in a volume ratio of 1:1 to obtain a rheumatoid artemisia stock solution with a concentration of 1 mg / mL, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use; Weigh chrysophanol, dilute it with ethanol:DMSO in a volume ratio of 5:13 to obtain a 2.00 mg / mL chrysophanol stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use; Weigh physcion methyl ether, dilute it with a mixture of ethanol and DMSO in a volume ratio of 5:13 to obtain a physcion methyl ether stock solution with a concentration of 0.572 mg / mL, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use; Weigh gallic acid and dilute it with 50% methanol to obtain a 1 mg / mL gallic acid stock solution, and dilute it with 50% methanol to a concentration of 100 μg / mL for later use; Weigh epicatechin, dilute with methanol to obtain an epicatechin stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Weigh scopoletin, dilute with 50% ethanol to obtain a scopoletin stock solution with a concentration of 1 mg / mL, and dilute with 50% methanol to a concentration of 100 μg / mL for later use; Preparation of mixed standard solution The above-mentioned single standard solutions of astragaloside IV, calycosin glucoside, ferulic acid, kaempferol, quercetin, hyperoside, aloe-emodin, rhein, rhein, chrysophanol, physophanol methyl ether, gallic acid, epicatechin and scopoletin, all of which have a concentration of 100 μg / mL, were mixed evenly, and diluted with 50% methanol to obtain a mixed standard solution in which the concentration of each compound was 2.00 μg / mL.

7. The metabolomics research method of Sanhuang Fang according to claim 4, characterized in that: Step (3) Animal model and serum preparation: Male SD rats were randomly divided into a normal control group and a renal interstitial fibrosis animal model group; 14 days after modeling, the rats in the normal and model groups were gavaged with the Xin Sanhuang Fang extract prepared in step (1) at a dose of 7.25 g / kg, and blood was collected from the rats' orbits at 0 h, 0.5 h, 1 h, 2 h, and 4 h after administration; Take 200 μL of plasma, add 800 μL of methanol, vortex for 1 min, centrifuge at 12000 rpm and 4°C for 10 min, take 900 μL of supernatant, blow dry at 40°C, add 100 μL of 50% methanol to the residue, vortex for 1 min, centrifuge at 12000 rpm and 4°C for 10 min, take 80 μL of supernatant, centrifuge at 12000 rpm and 4°C for 10 min to obtain a serum sample solution.

8. The method according to claim 3 or 4, characterized in that: The liquid chromatography conditions for the LC-Q-TOF / MS analysis are: Chromatographic column: Agilent SB C18, size 4.6 mm × 100 mm, 1.8 μm; Mobile phase: Phase A: 0.1% formic acid aqueous solution, Phase B: methanol and acetonitrile in a volume ratio of 1:1, column temperature: 40°C, gradient elution; the gradient elution program is as follows: 。 9. The method according to claim 3 or 4, characterized in that: The mass spectrometry conditions for the LC-Q-TOF / MS analysis are: The Q-TOF / MS analysis used the ESI source positive and negative ion scanning modes, the negative ion source voltage was -4500 V, the ion source temperature was 550 °C, the nebulizer gas was N2, and the primary mass spectrometer scanning range was: m / z 100~1000, DP: 80V; GS1: 50, GS2: 60, CUR: 20, CE: 10eV; IDA mode was used to collect secondary mass spectrometry data, and the collection range was: 90~1000, DP: 100V, CE: 25eV; CES: 15; the positive ion source voltage was 5500V, the ion source temperature was 550℃, the nebulizer gas was N2, and the primary mass spectrometry scanning range was: m / z 100~1000, DP: 100V; GS1: 50, GS2: 60, CUR: 20, CE: 10eV; IDA mode was used to collect secondary mass spectrometry data, and the collection range was: 90~1000, DP: 100V, CE: 30eV; CES: 15; IDA set the 10 highest peaks with response signal intensity > 100cps for secondary mass spectrometry scanning, and turned on dynamic background subtraction.

10. Use of the Chinese medicine composition according to claim 1 or 2 in the preparation of drugs for preventing renal interstitial fibrosis.

Citation Information

Patent Citations

  • Chinese medicinal composition for treating nephropathy and preparation thereof

    CN101313943A

  • Metabonomics research method of formula for tonifying kidney, clearing away heat and promoting blood circulation

    CN117368359A

  • Quality detection method of formula capable of tonifying kidney, clearing away heat and promoting blood circulation

    CN117388397A

  • Metabonomics research method of astragalus membranaceus-centella asiatica

    CN118348161A